Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer

摘要

We analyzed the responsiveness of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to 2 rare EGFR mutations, exon 19 insertion and exon 20 insertion (A763_Y764 insFQEA). The response rate for exon 19 insertion was 56%, and the median time to progression was 10.4 months. The response rate for exon 20 insertion (A763_Y764 insFQEA) was 73%, and the median time to progression was 5.0 months. Both showed sensitivity to EGFR TKIs.